KRAS and neoplasm: The biomarkers investigated included Programmed death-ligand 1 (PD-L1), Epidermal growth factor receptor (EGFR), Anaplastic lymphoma kinase (ALK), Kirsten rat sarcoma (KRAS), and others associated with tumor proliferation and therapeutic response.